| Effectiveness of timing strategies for delivery of individuals with placenta previa and accreta. | |
| | |
MedLine Citation:
|
PMID: 20859146 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: To compare strategies for the timing of delivery in individuals with placenta previa and ultrasonographic evidence of placenta accreta, and to determine the optimal gestational age at which to deliver individuals. METHODS: A decision tree was designed comparing nine strategies for delivery timing in an individual with placenta previa and ultrasonographic evidence of placenta accreta. The strategies ranged from a scheduled delivery at 34, 35, 36, 37, 38, or 39 weeks of gestation to a scheduled delivery at 36, 37, or 38 weeks of gestation only after amniocentesis confirmation of fetal lung maturity. Outcomes factored into the model included maternal intensive care unit admission, perinatal mortality, infant mortality, respiratory distress syndrome, mental retardation, and cerebral palsy. RESULTS: A scheduled delivery at 34 weeks of gestation was the preferred strategy and resulted in the highest quality-adjusted life years under the base case assumptions. Strategies awaiting confirmation of fetal lung maturity failed to result in better outcome than strategies that delivered at the corresponding gestational age without amniocentesis. After sensitivity analyses, delivery at 37 weeks of gestation without amniocentesis was the preferred strategy in limited situations, and delivery at 39 weeks of gestation was the preferred strategy only in unlikely situations. CONCLUSION: This decision analysis suggests the preferred strategy for timing of delivery in individuals with ultrasonographic evidence of placenta previa and placenta accreta under a variety of circumstances is delivery at 34 weeks of gestation. At any given gestational age, incorporating amniocentesis for verification of fetal lung maturity does not assist in the management of such individuals. LEVEL OF EVIDENCE: III. |
| | |
Authors:
|
Barrett K Robinson; William A Grobman |
Related Documents
:
|
19757386 - Immunoregulatory molecules in human placentas: potential for diverse roles in pregnancy. 17303496 - Effect of placenta previa on blood loss in second-trimester abortion by labor induction... 8430536 - Sonography of the gravid uterus and placenta: current concepts. 8215826 - Chronic intervillositis of the placenta. 18346976 - Intravenous immunoglobulin therapy in pregnant patients affected with systemic lupus er... 17377896 - Medical therapy for ectopic pregnancy. |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Obstetrics and gynecology Volume: 116 ISSN: 1873-233X ISO Abbreviation: Obstet Gynecol Publication Date: 2010 Oct |
Date Detail:
|
Created Date: 2010-09-22 Completed Date: 2010-10-22 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0401101 Medline TA: Obstet Gynecol Country: United States |
Other Details:
|
Languages: eng Pagination: 835-42 Citation Subset: AIM; IM |
Affiliation:
|
Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Prentice Women's Hospital, Northwestern University, Feinberg School of Medicine, Chicago, Illinois 60611, USA. b-robinson@md.northwestern.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Amniocentesis Betamethasone / administration & dosage Cerebral Palsy / epidemiology Decision Trees* Delivery, Obstetric* Female Fetal Organ Maturity Gestational Age* Glucocorticoids / administration & dosage Humans Infant, Newborn Lung / embryology Mental Retardation / epidemiology Placenta Accreta / mortality, therapy*, ultrasonography Placenta Previa / mortality, therapy*, ultrasonography Pregnancy Pregnancy Outcome* Respiratory Distress Syndrome, Newborn / epidemiology Ultrasonography, Prenatal Uterine Hemorrhage / epidemiology |
| Chemical | |
Reg. No./Substance:
|
0/Glucocorticoids; 378-44-9/Betamethasone |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Screening for prenatal substance use: development of the Substance Use Risk Profile-Pregnancy scale.
Next Document: Single umbilical artery risk factors and pregnancy outcomes.